Retinitis Pigmentosa and Inherited Retinal Dystrophy: What Treatments Actually Exist, and What's Coming - Myths Busted by Retina Specialist
Quick answer: Retinitis pigmentosa (RP) has no cure yet, but it is not untreatable. One gene therapy, Luxturna, is approved for a specific RPE65 mutation. Optogenetic therapy is under regulatory review. Supplements, treatment of complications and low-vision rehabilitation can help today. Genetic testing tells you which options, and which supplements, apply to you.
Luxturna, optogenetics, gene therapy... there are so many names going around that it is hard to know what is real, what is available, and what is still a trial. If you or someone you love has retinitis pigmentosa, or what we more broadly call an inherited retinal dystrophy, the same questions come up in my clinic again and again. What is the treatment? Which genetic test should I do? Am I going to go blind?
Hi, I'm Dr. Mayank Bansal, a vitreo-retinal surgeon practising in New Delhi. In this article I'll answer those questions plainly, bust a few myths, and tell you where things honestly stand in October 2026.
What Is Retinitis Pigmentosa, and How Is It Different From an Inherited Retinal Dystrophy?
Retinitis pigmentosa (RP) is one subtype of a much broader group called inherited retinal dystrophies (IRDs). When we examine the retina and see small black pigment deposits in the periphery, the side parts of the retina, we call it RP.
The name is historical. "Retinitis" suggests inflammation, but RP is a genetic condition in which retinal cells slowly break down over time.
Some IRDs look very different. Stargardt disease and cone-rod dystrophies mainly affect the macula, the central part of the retina. Today, these conditions are increasingly classified by the underlying gene rather than by how the retina looks.
RP is not rare in India. LV Prasad Eye Institute reports that a 15-year study in South India found RP to be the second leading cause of new cases of blindness there.
What Are the Symptoms of Retinitis Pigmentosa?
The most common early symptom is night blindness: difficulty seeing in dim light. Once evening sets in, it becomes hard to recognise objects. In children, parents may notice that the child struggles to move around in the dark.
Other symptoms include:
Narrowing of side vision. The field of vision shrinks slowly until only a central "tunnel" is left.
Central vision problems in some people. Letters may look wavy, or there may be a constant dark spot. This is what we call a macular dystrophy.
Sensitivity to bright light and loss of colour vision.
RP can start in early childhood, in adolescence, or around the 20s and 30s. Loss of side vision is far more typical than early loss of central vision.
Why Does It Happen? Genes, Proteins and Retinal Cells
Our genes carry the instructions for making proteins, and proteins keep our cells working. In RP, a mutation means the correct protein is not made. The retinal cells then stop functioning properly and, over time, degenerate.
Many different genes can be responsible, and RP can be inherited in different ways. Sometimes it is part of a wider syndrome. Usher syndrome, for example, combines RP with hearing loss, so a hearing check is worthwhile too. Rarely, RP is caused by medicines, infections or injury.
Why Genetic Testing Matters
A little history helps. The human genome was mapped in the early 2000s, genetic testing became commercially available from around 2010, and the first gene therapy for the eye arrived in 2017. Since then, knowing the exact mutation has become critical.
In practice, a genetic test can:
Confirm the exact type of dystrophy and help predict how it may change over time.
Show whether you may qualify for an approved gene therapy or a clinical trial.
Tell you what to avoid. For example, vitamin A supplements are not recommended if the gene involved is ABCA4 (Stargardt disease).
Help your family, through genetic counselling, understand their own risk.
The test can be a meaningful expense depending on the panel, and that puts some families off. My advice is still to discuss it with a retina specialist. Even if no therapy fits today, you will be ready when one does. You can read more on my eye genetics page.
Myth: "Can't I Just Get an Eye Transplant?"
I hear this question a lot. A corneal transplant is real and successful. The cornea is the clear front window of the eye, and it has no blood supply, which makes it one of the safer tissues to transplant.
The retina and optic nerve are different. They are neural tissue, like the brain. We do not do brain transplants, and for the same reason we cannot transplant a retina: it cannot integrate and survive in a new host. Whole-eye transplantation has only been attempted experimentally and has not restored sight so far.
So no, an eye transplant does not cure retinitis pigmentosa.
What Treatments Exist for Retinitis Pigmentosa Today?
Here is the honest picture, as of October 2026.
Option | What it is | Status | Who it may suit |
Luxturna (voretigene neparvovec) | Gene therapy delivered by subretinal injection during surgery | Approved by the US FDA (2017) and the EU regulator, EMA | People with vision loss from confirmed biallelic RPE65 mutations who still have enough healthy retinal cells |
MOGENRY (MCO-010), optogenetic therapy | One-time intravitreal injection that makes surviving retinal bipolar cells light-sensitive | Not approved. FDA accepted its application for RP with severe vision loss (Sept 2026) . Japan's PMDA granted priority review for IRDs (Oct 2026) | Designed to work whatever the specific gene mutation, if approved |
Gildeuretinol (ALK-001) | Oral, modified (deuterated) vitamin A | Investigational. Not approved | Stargardt disease |
Tinlarebant | Oral drug that reduces vitamin A-derived toxic by-products | Investigational. FDA decision date set for 12 February 2027 | Stargardt disease |
Supplements (lutein, omega-3, sometimes vitamin A) | Nutritional support | Available. Evidence is modest | Individualised, after genetic testing and specialist advice |
Low-vision rehabilitation, and treatment of cataract and macular swelling | Aids, training and treatment of complications | Available today | Almost everyone with RP |
Luxturna: The One Approved Gene Therapy
Luxturna was approved by the US FDA in 2017 for inherited retinal dystrophy caused by mutations in both copies of the RPE65 gene. The EU authorisation requires that enough functioning retinal cells remain. It is delivered by an injection under the retina.
RPE65 is not among the most common causes, especially among the patients I see in India. Access in India is limited and would need to be discussed case by case. But it matters: it proves that gene therapy for the retina works, and it is the reason everyone with a retinal dystrophy should consider genetic screening.
Optogenetics: The Most Promising Option on the Horizon
Of everything in development, optogenetics excites me the most, because it does not depend on knowing your mutation.
A viral vector carries a gene for a light-sensitive molecule into the retina's bipolar cells through an injection into the eye. Whenever light falls on these cells, they generate a signal, which travels through the ganglion cells and the optic nerve to the brain. The dying photoreceptors are bypassed.
The company behind it, Nanoscope Therapeutics, has two regulatory milestones so far: the FDA accepted its application for retinitis pigmentosa with severe vision loss, and Japan granted priority review for inherited retinal dystrophies. Neither is an approval. I have explained the details in my article on what MOGENRY's filings actually mean.
Stargardt Disease: Avoid Vitamin A, and Watch the Pipeline
If your gene is ABCA4 (Stargardt disease), I advise against vitamin A supplements. In this disease, toxic by-products made from vitamin A build up in the retina.
Two oral drugs aimed at that pathway are in late-stage development. In the phase 3 DRAGON trial, tinlarebant slowed the growth of retinal lesions by about 35.7% compared with placebo. Gildeuretinol slowed lesion growth by 21.6% over two years in a phase 2 trial. Both are still investigational.
One honest caveat: these results are on retinal imaging. Slowing lesion growth is not the same as restoring vision, and the DRAGON trial did not show a benefit in visual acuity.
Supplements: What Is Reasonable
The National Eye Institute says vitamin A may help slow vision loss in the common forms of RP, but too much can cause liver problems. Fish oil and lutein may also help. In practice, many specialists use macular pigment supplements containing lutein, zeaxanthin and omega-3 fatty acids.
The evidence is modest, and this is not a cure. Please do not start vitamin A on your own. The right choice depends on your gene and your dose.
Rehabilitation and Treatable Complications
People with RP are more likely to develop other eye problems, including refractive errors, cataract, and small pockets of fluid in the central retina called cystoid macular edema. These can often be treated, which is a good reason for regular eye exams.
Low-vision aids and rehabilitation programmes help people make the most of the vision they have.
What Can You Do Yourself to Protect Your Vision?
Get regular follow-up. Visual fields and retinal imaging let us track change and catch treatable problems early.
Reduce avoidable stress on the retina. Poor sleep, alcohol and tobacco are thought to add oxidative stress to retinal cells, and I have seen patients do worse when these pile up. Controlled human evidence is limited, but these changes are low-risk and good for your health anyway.
Ask about genetic testing and counselling, for yourself and for relatives who may be at risk.
Be careful with "stem cell treatment" offers. No stem-cell therapy is approved for RP. If a clinic advertises it as a treatment, ask whether it is part of an approved clinical trial.
When Should You See a Retina Specialist?
Please book an examination if you notice:
Increasing difficulty seeing at night or in dim light
Side vision slowly shrinking, or bumping into objects at the edges
A child who struggles to move around in the dark
A family history of retinal degeneration or early vision loss
Frequently Asked Questions
Is retinitis pigmentosa curable? Not yet. There is no cure for RP today. But some people have an approved option (Luxturna, for a specific RPE65 mutation), and optogenetic therapy is under regulatory review. Supplements, treatment of cataract or macular swelling, and low-vision rehabilitation can also help you make the most of your vision. Genetic testing shows which options apply to you.
Will I go completely blind with retinitis pigmentosa? The pace varies widely from person to person, even within the same family. The National Eye Institute notes that most people with RP eventually lose most of their sight. That is why early diagnosis, regular monitoring, treatment of complications and rehabilitation matter, and why it is worth staying in touch with a retina specialist as new treatments arrive.
Do I need genetic testing for retinitis pigmentosa, and what will it tell me? I recommend discussing it with your retina specialist. A genetic test identifies the gene behind your condition. That shows whether you may be eligible for a gene therapy or clinical trial, whether a supplement such as vitamin A should be avoided, and what the risk may be for family members. It can be a meaningful expense, so ask which panel suits you.
Should I take vitamin A if I have retinitis pigmentosa? Not on your own. The National Eye Institute says vitamin A may help slow vision loss in common forms of RP, but too much can cause liver problems. In Stargardt disease (ABCA4 gene), vitamin A supplements are not recommended. Confirm your diagnosis and gene first, then decide the dose with your doctor. High-dose vitamin A is also unsafe in pregnancy.
Is optogenetic therapy (MOGENRY) available in India? No. MOGENRY is not approved anywhere yet. The US FDA has accepted Nanoscope Therapeutics' application for retinitis pigmentosa with severe vision loss, and Japan's regulator has granted priority review for inherited retinal dystrophies. Neither filing covers India. If it is approved abroad, availability here would follow a separate regulatory process.
Can stem cells or an eye transplant cure retinitis pigmentosa? No. The retina and optic nerve are neural tissue that cannot be transplanted, and whole-eye transplants remain experimental. No stem-cell therapy is approved for RP. Under national ICMR guidelines, stem-cell treatment for such conditions is investigational and should be offered only within approved clinical trials, so be cautious of clinics advertising it as a treatment.
Next Step
If you or someone in your family has retinitis pigmentosa, Stargardt disease or another inherited retinal dystrophy, the first step is a thorough retinal evaluation and a conversation about genetic testing.
You can book an in-person consultation at Claritas Eye & Retina Institute, B2 Panchsheel Enclave, New Delhi - 110017, or begin with a video consultation. A video consultation can start the conversation, but it does not replace an in-person retinal examination and the imaging or electrophysiology tests that may be needed.
I will update this article when there is real news from the regulators.
About the Author
Dr. Mayank Bansal, MD (AIIMS), MRCSEd, FRCS (Glasgow), FACS (USA) Vitreo-retinal surgeon and Director, Claritas Eye & Retina Institute, B2 Panchsheel Enclave, New Delhi 110017. ICO fellowship in Vitreo-Retinal Surgery at UCLA (2014).
This article is for general information and is not a substitute for an in-person consultation. MOGENRY, gildeuretinol and tinlarebant are investigational and are not approved or available for routine use. Information reflects public announcements as of October 2026 and may change.
References
National Eye Institute. Retinitis Pigmentosa. https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/retinitis-pigmentosa (last updated Aug 2025)
European Medicines Agency. Luxturna (voretigene neparvovec): EPAR summary. https://www.ema.europa.eu/hr/medicines/human/EPAR/luxturna
Nanoscope Therapeutics. FDA acceptance of the Biologics License Application for MOGENRY in retinitis pigmentosa with severe vision loss, 9 Sept 2026. https://nanostherapeutics.com/2026/09/09/nanoscope-therapeutics-announces-u-s-food-and-drug-administration-acceptance-of-biologics-license-application-for-mogenry-for-the-treatment-of-retinitis-pigmentosa-with-severe-vision-loss/
Nanoscope Therapeutics. PMDA acceptance and priority review of the New Drug Application for MOGENRY in Japan, 1 Oct 2026. https://nanostherapeutics.com/2026/10/01/nanoscope-therapeutics-announces-pmda-acceptance-and-priority-review-of-new-drug-application-for-mogenry-in-japan-for-the-treatment-of-inherited-retinal-dystrophies/
Healio. Stargardt disease therapy granted priority review, PDUFA date (tinlarebant). https://www.healio.com/news/ophthalmology/20260925/stargardt-disease-therapy-granted-priority-review-pdufa-date
Clinical Trials Arena. Belite Bio seeks US approval for tinlarebant in Stargardt disease (DRAGON phase 3). https://www.clinicaltrialsarena.com/?p=245152
Healio. FDA grants rare pediatric disease and fast track designations to gildeuretinol (TEASE-1 results). https://cm.healio.com/news/ophthalmology/20241120/fda-grants-rare-pediatric-disease-fast-track-designations-to-stargardt-disease-therapy
L V Prasad Eye Institute. Retinitis Pigmentosa. https://www.lvpei.org/eye-conditions/retinitis-pigmentosa/ (cites Parameswarappa D et al., Indian J Ophthalmol 2023;71(3):902-908)
Comments